The knowledge is growing to address ellagic acid (EA) as a promising anti-cancer agent in colon, as well as, other types of human cancers. Up-regulation of β-catenin in colon cancer supports tumorigenic pathways in numerous aspects, which makes the need pressing to target this pathway.
Introduction:
Colon cancer is a leading cause of death worldwide (1) . Traditional treatment modalities have shown limited success to improve patients' quality of life, which makes a pressing need to innovate novel therapies exerting no harm on normal tissues. Ellagic acid (EA) has received a significant interest from researchers as a potential promising therapeutic agent for colon, as well, as other types of human cancers. Ellagic acid antiproliferative potential was reported in human colon cancer cell line model (2) . Anti-cancer effects of ellagic acid include: induction of apoptosis; inhibition of angiogenesis; interference with DNA-carcinogen binding; anti-inflammatory and anti-viral effects, and overcoming drug resistance (3) . Inhibition of mammalian target of rapamycin (mTOR) by ellagic acid in prostate cancer cells was also reported (4) . Inhibition of breast cancer stem cells proliferation and migration potential was also reported following treatment with ellagic acid. This inhibition was associated with interruption of ACTN4/β-catenin interaction and consequent degradation of β-catenin (5). Β-catenin, a main component of Wnt pathway has been frequently reported to be mutated in chemically induced colon cancer in rats; the oncogene c-MYC and cyclin D1, a cell cycle regulator, are downstream targets of Wnt/β-catenin pathway (6) . It has also been reported that this pathway supports cancer initiation as well as progression (7) . At this end, β-catenin has been recognized as a potential target for cancer chemoprevention in various cancer models including colon (8) (9) (10) . Cytochrome 1B1 (CYP 1B1) is a xenobiotic metabolizing enzyme belonging to a large family of cytochrome p450
proteins. The enzyme has been shown to contribute to activation of numerous procarcinogens converting them to active carcinogens participating to human carcinogenesis. Hence, the enzyme has attracted attention as another therapeutic target in tumors that overexpress CYP 1B1 (11). CYP 1B1 was proposed as a promoting factor in human colon cancer. In this respect, it was reported that CYP 1B1 is overexpressed in colon cancer tissues as compared to the normal samples (12) . Likewise, overexpression of CYP 1B1 was also reported in non-small cell lung cancer (NSCLC) highlighting the enzyme as a biomarker for disease progression (11). The main aim of the current study was to investigate the effect of ellagic acid on β-catenin level and phosphorylation. In addition, the effect of ellagic acid on CYP 1B1 was also investigated.
This investigation would help to assess the concordance between the anti-proliferative potential of ellagic acid and its potential to regulate cell migration and other cellular functions via regulation of β-catenin or CYP 1B1 in two colon cancer cell lines with different genetic background.
Material and methods:

Materials:
CaCo-2 (K-Ras+/ p53-) and 
3-Cell cycle analysis:
Cells were sub-cultured; counted, and plated in tissue culture petri dishes at a density of 1x10 Invitrogen™, Thermo Fisher Scientific, USA.).
Change in absorbance reflects the levels of total and phospho-β catenin in cell lysate.
Cytochrome 1B1 levels were estimated in cell lysate according to the procedure described in the datasheet of Enzyme-linked Immunosorbent Assay Kit for Cytochrome P450 1B1 (CYP1B1; detection range is 1.56-100 ng/ml) (#SED297Hu; Cloud-Clone Corp., Katy, Texas, USA.).
5-Statistical analysis:
Statistical comparisons were done using student ttest and difference between pairs was considered statistically significant when p values are ≤ 0.05.
Data analysis was done using Graphpad Prism The broad-spectrum anti-tumor effects of ellagic 
